Melanoma – media

BMS’ Opdivo/Yervoy improves long-term survival for melanoma patients

Bristol Myers Squibb’s Opdivo (nivolumab) plus Yervoy (ipilimumab) combination has demonstrated ‘durable improvement in survival’, according to new long-term data from a Phase III trial. According to 6.5 year data from CheckMate-067, median overall survival (OS) for patients with advanced melanoma was 72.1 months with Opdivo plus Yervoy, compared with 36.9 months for patients received Opdivo alone and 19.9 months for Yervoy monotherapy. In a statement, BMS said this represented the longest reported median OS in a Phase III advanced melanoma trial. Opdivo plus Yervoy also demonstrated a 6.5-year progression-free survival (PFS) rate of 34%, versus 29% and 7% for Opdivo alone and Yervoy alone, respectively. In addition, of the 49% of patients who were alive and in follow-up, 77% who received Opdivo plus Yervoy, 69% of Opdivo-treated and 43% of Yervoy-treated patients have been off treatment and never received subsequent systemic therapy. Also, among melanoma patients with BRAF-mutant tumours, ...
- Source: drugdu
- 143
- May 24, 2021
Melanoma
BMS’ Opdivo plus LAG-3 antibody relatlimab show promise in melanoma

Bristol Myers Squibb (BMS) has revealed top-line data from a Phase II/III trial evaluating its PD-1 inhibitor Opdivo plus its investigational anti-LAG-3 antibody relatlimab in previously untreated metastatic or unresectable melanoma. The RELATIVITY-047 trial is evaluating a fixed-dose combination of Opdivo (nivolumab) and relatlimab compared to Opdivo alone in these patients. According to BMS, the trial met its primary endpoint of progression-free survival, with follow-up for the secondary endpoint of overall survival still ongoing. Although the company did not disclose the actual figures for the combination treatment, BMS said it would present the results at an upcoming meeting and discuss the findings with regulatory authorities. Lymphocyte-activation gene 3 (LAG-3) is expressed on effector T cells and regulatory T cells (Tregs). It regulates an inhibitory immune checkpoint pathway that limits the activity of T cells, which is believed to cause an impaired ability to attack tumour cells. In cancer, T cells exhibit progressive exhaustion ...
- Source: drugdu
- 301
- April 1, 2021
Melanoma
Skin Examination through Machine Learning Could Result in Inaccurate Diagnoses for People of Color, JAMA Op-Ed Remarks

Dermatology apps faced controversies when they were first launched but soon received respite when machine learning (ML) technologies were used for digital skin examinations.
- Source: MobiHealthNews
- 659
- August 13, 2018
digital health Melanoma Researches
Sunscreen Lotions in Childhood can Reduce Melanoma Risk in Adulthood

It is estimated that one person dies every hour as a result of melanoma in the United States. In the past decade, the count has been increased by 53 percent. A recent study suggests that regular use of sunscreen lotions in childhood can reduce the risk of melanoma by 40 percent in young adulthood.
- Source: HealthLine
- 677
- August 8, 2018
health tips Melanoma Researches
Array BioPharma gets FDA Approval for Melanoma Combo

The U.S, Based Array BioPharma received FDA approval for its much-awaited BRAFTOVI capsules with the combination of MEKTOVI tablets for the treatment of patients with metastatic melanoma with a BRAFV600E or BRAFV600K mutation.
- Source: FiercePharma
- 593
- June 28, 2018
cancer Melanoma New Approvals
Novartis combination adjuvant therapy Tafinlar® + Mekinist® receives FDA Breakthrough Therapy Designation

Novartis today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) for the adjuvant treatment of patients with stage III melanoma with a BRAF V600 mutation following complete resection. Tafinlar in combination with Mekinist is in development to become the first adjuvant treatment specifically for melanoma patients with a BRAF V600 mutation.
- Source: novartis
- 709
- October 24, 2017
BTD FDA Melanoma New Approvals
New findings explain how UV rays trigger skin cancer

Melanoma, a cancer of skin pigment cells called melanocytes, will strike an estimated 87,110 people in the U.S. in 2017, according to the Centers for Disease Control and Prevention. A fraction of those melanomas come from pre-existing moles, but the majority of them come from sources unknown - until now.
- Source: Medicalxpress
- 566
- October 19, 2017
Melanoma

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.